There is one clinical trial.
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation) and to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination with ipilimumab versus ipilimumab monotherapy (for dose expansion).
Description: Progression free survival rates (PFS rates)
Measure: Progression Free Survival rates (PFS rates) Time: at 24 weeks and at 1 yearDescription: Overall Survival Rates (OS rates)
Measure: Overall Survival Rates (OS rates) Time: at 1 year and at 2 yearsDescription: Objective Response Rate (ORR)
Measure: Objective Response Rate (ORR) Time: up to 2.4 years